AzTrials
AzTrials

DiabetesPhase 2ILOFLOWNCT01774058

The Arterial Measurement of the Blood Flow Volume After Iloprost Stimulation

A Phase 2 study testing Ilomedin in people with Diabetes and Arteriosclerosis, run by Prim PD Dr Afshin Assadian at 1 site in Austria.

Unknown status

Status not confirmed. The sponsor has not verified this record for over two years, so it may be out of date.

Official record
Search all trials

Trial summary

A prospective case-control study was performed to investigate the effect of iloprost on the intraoperative flow volume in diabetic and non-diabetic patients as well as the effect of peripheral neuropathy in patients with peripheral arterial occlusive disease (PAOD) undergoing arterial reconstruction (primary… Read more about this study

Who is it for?
Ages 18 years and older
What is being tested?
Ilomedin
Type of treatment
Injection or infusion
Could I receive a placebo?
No, everyone receives an active treatment
How many people
100 participants
Where
1 siteAustria
Study dates
Oct 2012to Jun 2019
Phase
Phase 2
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 years and older
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Who may be able to join

  • patients with diabetes and non diabetes
  • patients with peripheral artery occlusive disease and who undergo surgical treatment in distal vessels
  • spinal anesthesia
  • written consent

Who cannot join

  • pregnancy
  • heart attack the last 6 months
  • stroke the last 6 months
  • hypotension
  • edema of the lungs
  • heart failure
Show all 13Show fewer
  • heart disease
  • chronic obstructive pulmonary disease (COPD)
  • ulcus ventriculi
  • renal disease
  • coronary disease
  • immaturity
  • general anesthesia

Trial locations and contacts

1 site in 1 country.

Afshin Assadian, Prim. PD Dr. contact

+34(0)1491504101

afshin.assadian@wienkav.at

Kornelia Hirsch, Dr. contact

+34(0)1491504101

kornelia.hirsch@wienkav.at

Austria1 site, 1 recruiting
  • Department of vascular and endovascular surgery, Georg Hagmüller Institute for Vascular Research Wilhelminenhospital

    Vienna, 1160

    Afshin Assadian, Prim PD Dr, +34(0)1491504101, afshin.assadian@wienkav.at

    Kornelia Hirsch, Dr, +34(0)1491504101, kornelia.hirsch@wienkav.at

    Recruiting

Other trials in Austria

About this study

Official title: The Intraoperative Arterial Measurement of the Blood Flow Volume After Iloprost Stimulation in Diabetics and Non-diabetics: Implication for Outcome-prediction and Perioperative Therapy

A prospective case-control study was performed to investigate the effect of iloprost on the intraoperative flow volume in diabetic and non-diabetic patients as well as the effect of peripheral neuropathy in patients with peripheral arterial occlusive disease (PAOD) undergoing arterial reconstruction (primary endpoint).

100 patients undergoing femoral artery reconstruction or femorodistal bypass surgery were included. Prior to surgery, peripheral nerve conduction velocity was measured. Blood flow volume at the common femoral artery was assessed using a Doppler flowmeter (Sono TT FlowLab; ) before reconstruction, prior to the intraarterial application of 3000ng of iloprost and 5 and 10 minutes afterwards. Peripheral resistance units (PRU) were calculated as a function of mean systemic arterial pressure (MAP) and flow volume (VF): PRU = MAP (mmHg) / VF (ml/min).

Read the detailed description

The therapeutic properties of prostanoids appear to be primarily due to its vasodilative effect. However, the inhibition of platelet aggregation with a limitation of thrombus formation and the inhibition of the adhesion of leucocytes to endothelial lesions also help to improve blood flow in the peripheral circulation .

It is currently unclear which effects of prostanoids are predominant for diabetic patients. The present study was performed to assess potential differences of iloprost efficiency for patients with or without type II diabetes mellitus with or without peripheral neuropathy.

The study was a single center, controlled, non- randomized interventional study. All patients provided their written consent. The study has been approved by the Ethics Committee of the city of Vienna in 2012 (EC nr: 11-144-0512) and was extended annually for the last two years. Performance of the study complied with the World Medical Association Declaration of Helsinki regarding ethical conduct of research involving human subjects.

The study was designed to enroll 100 consecutive patients with peripheral arterial occlusive disease undergoing surgical reconstruction of the inguinal arteries and/or femorodistal bypass surgery. Indication for surgery included PAOD Fontaine stage IIb (waking distance less than 200 meters), III (rest pain) or IV (tissue loss). Surgical procedures were planned and the absence of inflow stenoses verified based on MRI or CT angiography. Exclusion criteria for participation in the study comprised contraindications for the application of iloprost as well as a planned spinal anesthesia. Patients were divided into two groups based on being diabetic type II or non-diabetic. Before surgery measurement of nerve conduction velocity was performed by a trained nurse at the Department of Physiotherapy in order to determine the presence of neuropathy.

Surgery was performed under general anesthesia via a longitudinal skin incision. After systemic administration of 5000 IU of unfractionated Heparin, the peripheral vessels were clamped. After longitudinal arteriotomy, thrombendarterectomy of the common femoral artery was performed in all cases, extending into the deep femoral artery and superficial femoral artery when necessary. In some cases, this was followed by femoropopliteal bypass surgery. Provided the systolic blood pressure was equal to or above 100 mmHg at the end of the reconstruction, 3000 ng of iloprost (Ilomedin), diluted in 15ml saline solution, were injected into the common femoral artery. Distal to the injection site doppler flow measurement was performed at the common femoral artery prior to arteriotomy, prior to the intraarterial application of iloprost, 5 and 10 minutes afterwards, using the Sono TT FlowLab instrument (em-Tec GmbH, Munich). Transmission heads were selected to fit tightly around the reconstructed vessel without producing a stenosis. During the procedure, systemic arterial blood pressure was continuously documented using a pressure transducer connected to an intraarterial cannula placed in the radial artery of the forearm. The result of the arterial reconstruction was routinely checked by intraoperative on- table angiography. Before discharge from the hospital the surgical reconstruction was controlled by duplex ultrasound as well as an assessment of the ankle brachial index.

Statistical analysis was performed with SPSS 15.0 for Windows (SPSS Inc, Chicago, Ill). To correct all measurements of flow volume for blood pressure, peripheral resistance units (PRU) were calculated as a function of mean systemic arterial pressure (MAP) and flow volume (VF): PRU = MAP (mmHg) / VF (ml/min).

The patient population was stratified by the presence of diabetes and by the presence of peripheral neuropathy in the operated limb. Kolmogorov-Smirnov testing confirmed normal distribution of all continuous variables. Descriptive statistics (mean, standard deviation, range) were applied to acquired data, and tests for dependent or independent variables were used for comparison of continuous variables, as applicable. Categorical variables were expressed as frequencies and percentages, and differences between groups were investigated by the Pearson Chi -square and Fisher exact tests. Patient characteristics potentially modulating the effect of iloprost were investigated by linear regression analysis. P values < 0.05 were considered significant.

Being tested
Ilomedin
Keywords
blood flow volume, ilomedin, measurement, intraarterial, neuropathy
Medical subject headings
Diabetes Mellitus, Arteriosclerosis, Peripheral Arterial Occlusive Disease 1

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • IlomedinDrug

    Also called Product Code 1-22460, ATC Code: B01AC11, concentrate and solvent for injection

    3000ng ilomedin in 15ml salt water will be injected intraarterial into the common femoral artery over 2 minutes for one time,then the investigators will measure the blood flow volume after 5 and then after 10 minutes on the common femoral artery. The patients will be observed by the anaesthesiologist. The patient will get ilomedin one day before the surgery and then for 6 day after surgery into the vein. (10microgramm/o,5ml in 250ml salt water)

Study groups in NCT01774058
Study groupRoleWhat they receive
Ilomedin, bloodflow volume, measurement,ExperimentalSurgery was performed under general anesthesia via a longitudinal skin incision. After systemic administration of 5000 IU of unfractionated Heparin, the peripheral vessels were clamped. Following a longitudinal arteriotomy, thrombendarterectomy of the common femoral artery was performed in all cases, extending into the deep femoral artery and superficial femoral artery when necessary. At the end of the reconstruction, 3000 ng of iloprost (Ilomedin), diluted in 15ml saline solution, were administered into the common femoral artery. Distal to the injection site doppler flow measurement was performed at the common femoral artery prior to arteriotomy, prior to the intraarterial application of iloprost and 5 and 10 minutes afterwards, using the Sono TT FlowLab instrument. During the procedure, systemic arterial blood pressure was continuously documented using a pressure transducer connected to an intraarterial cannula placed in the radial artery of the forearm.
Receives: Drug: Ilomedin

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. The measurement of the blood flow volume is done with the Sono TT FlowLab (em-Tec GmbH, Munich) ultrasound instrument on the common femoral artery in diabetics and non-diabetics after ilomedin administration.

    Before surgery reconstruction the first measurement with the Sono TT FlowLab (em-Tec GmbH, Munich) ultrasound instrument will be done on the common femoral artery and then after surgery reconstruction. Therefore there will be different measuring heads exactly fitting around the vessels. Then the administration of 3000ng Ilomedin® in 15ml saline will be injected into the common femoral artery via a a cannula over two minutes if the systolic blood pressure of the patient is over 100mm Hg. The blood flow volume will be measured again after five and ten minutes on the same point. Those results will be documented.

    Measured: 6 weeks after surgery

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted23 Jan 2013 (estimated)
  2. Study startOct 2012
  3. Primary completionJun 2019 (estimated)
  4. Study completionJun 2019 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrolment
100 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT01774058
Sponsor's protocol ID
ILOFLOW2.0
Acronym
ILOFLOW
Status last verified
Oct 2018
First submitted
7 Jan 2013
Last updated
17 Oct 2018
Results posted
No
Data monitoring committee
No

Questions about this trial

What is this clinical trial studying?

A Phase 2 study testing Ilomedin in people with Diabetes and Arteriosclerosis, run by Prim PD Dr Afshin Assadian at 1 site in Austria.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 4 inclusion and 13 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: status not confirmed, as of the sponsor's last update on 17 Oct 2018. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in Austria. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

What does this phase mean?

Phase 2 studies give the treatment to a larger group to see whether it has the intended effect and to keep checking safety.

Not every study follows the same path, and some studies (observational studies, device studies) have no phase.

Are results available for this study?

Results are not available in the source record.

How can a doctor refer a patient or contact the research team?

Contact Afshin Assadian, Prim. PD Dr. (+34(0)1491504101, afshin.assadian@wienkav.at), or a site near the patient. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

The measurement of the blood flow volume is done with the Sono TT FlowLab (em-Tec GmbH, Munich) ultrasound instrument on the common femoral artery in diabetics and non-diabetics after ilomedin administration. (time frame: 6 weeks after surgery). It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 17 Oct 2018.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in